Provention Bio’s Crohn’s Disease Trial is Fully Enrolled, with Top-line Results Expected Later in Year

Provention Bio’s Crohn’s Disease Trial is Fully Enrolled, with Top-line Results Expected Later in Year
Provention Bio has completed patient enrollment for a Phase 2a clinical trial evaluating the efficacy and safety of its investigational oral therapy — PRV-6527 — for moderate to severe Crohn's disease, and plans to report its first top-line results in the fourth quarter of this year. The company believes the small molecule inhibitor will prevent disease flares (relapses) or disease progression, with longer-term effects, by blocking the first steps of the inflammatory process from happening in the gut, according to a press release. The Phase 2a PRINCE (PRovention Investigation in Crohn's DiseasE) clinical trial (NCT03854305) is a proof-of-concept study to evaluate PRV-6527’s anti-inflammatory benefit, both in terms of clinical manifestations and gut tissue inflammation, after 12 weeks of treatment. Enrollme
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *